Dilemmas in chronic/persistent pain management

Disease-a-Month

Volumn 56, Issue 4, 2010, Pages 233-250

  Katz, Warren A ^a   Barkin, Robert L ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; CARBAMAZEPINE; CELECOXIB; CODEINE; DEXTROPROPOXYPHENE; DIHYDROCODEINE; FENTANYL; GABAPENTIN; HYDROCODONE; HYDROMORPHONE; IBUPROFEN; LEVORPHANOL; METHADONE; MORPHINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE; OXYCODONE; OXYMORPHONE; PARACETAMOL; PLACEBO; PREGABALIN; ROFECOXIB; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TOPIRAMATE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ACUTE KIDNEY FAILURE; ANALGESIA; ANALGESIC ACTIVITY; ANKYLOSING SPONDYLITIS; ARTHRITIS; BLEEDING; CARDIOVASCULAR RISK; CHRONIC PAIN; COGNITIVE DEFECT; CONSTIPATION; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DIZZINESS; DOSE RESPONSE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RESPONSE; DYSMENORRHEA; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART DISEASE; HUMAN; HYPERKALEMIA; HYPERTENSION; INSOMNIA; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MYOCLONUS; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NOCICEPTION; OSTEOARTHRITIS; PAIN; PATHOPHYSIOLOGY; QUALITY OF LIFE; RESPIRATION DEPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SEDATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SWEATING; URINE RETENTION; VERTIGO; VOMITING; XEROSTOMIA;

ANALGESICS; CHRONIC DISEASE; COST OF ILLNESS; HUMANS; PAIN;

EID: 77950337129     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.disamonth.2009.12.006     Document Type: Review

References (113)

1. Glickman-Simon R. Persistent pain and palliative care. Medscape coverage of the American College of Physicians 2006 Annual Session [web site], Accessed January 24, 2007. http://www.medscape.com/viewarticle/535720.
2. Siddall P.J., Cousins M.J. Persistent pain as a disease entity: implications for clinical management. Anesth Analg 2004, 99:510-520. table.
3. New directions in pain research: I Department of Health and Human Services, National Institutes of HealthNational Institutes of Health, [web site], Accessed February 21, 2007. http://grants.nih.gov/grants/guide/pa-files/PA-98-102.html.
4. Katz W.A. Musculoskeletal pain and its socioeconomic implications. Clin Rheumatol 2002, 21:S2-S4.
5. 1999 National Pain Survey Ortho-McNeil Pharmaceutical, [web site], Accessed February 21, 2007. http://www.chiro.org/LINKS/FULL/1999_National_Pain_Survey.html.
6. Allen H., Hubbard D., Sullivan S. The burden of pain on employee health and productivity at a major provider of business services. J Occup Environ Med 2005, 47:6581-6670.
7. Stewart W.F., Ricci J.A., Chee E., et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003, 290:2443-2454.
8. Hu X.H., Markson L.E., Lipton R.B., et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999, 159:813-818.
9. Ricci J.A., Stewart W.F., Chee E., et al. Pain exacerbation as a major source of lost productive time in US workers with arthritis. Arthritis Rheum 2005, 53:673-681.
10. Rizzo J.A., Abbott T.A., Berger M.L. The labor productivity effects of chronic backache in the United States. Med Care 1998, 36:1471-1488.
11. Barkin R.L., Barkin S.J., Barkin D.S. Pharmacotherapeutic management of pain with a focus directed at the geriatric patient. Rheum Dis Clin North Am 2007, 33:1-31.
12. Barkin R.L., Barkin S.J., Barkin D.S. Perception, assessment, treatment, and management of pain in the elderly. Clin Geriatr Med 2005, 21:465-490. v.
13. Barkin R.L., Schwer W.A., Barkin S.J. Recognition and management of depression in primary care: a focus on the elderly. A pharmacotherapeutic overview of the selection process among the traditional and new antidepressants. Am J Ther 2000, 7:205-226.
14. Barkin R.L., Lubenow T.R., Bruehl S., et al. Management of chronic pain. Part II. Dis Mon 1996, 42:457-507.
15. Brookoff D. Chronic pain: 1. A new disease?. Hosp Pract (Minneap) 2000, 35:45-52. 59.
16. Watkins J.C., Jane D.E. The glutamate story. Br J Pharmacol 2006, 147(suppl 1):S100-S108.
17. Gilron I., Watson C.P., Cahill C.M., et al. Neuropathic pain: a practical guide for the clinician. CMAJ 2006, 175:265-275.
18. Dellemijn P. Are opioids effective in relieving neuropathic pain?. Pain 1999, 80:453-462.
19. Rowbotham M.C. Efficacy of opioids in neuropathic pain. Neuropathic Pain: Pathophysiology and Treatment, Progress in Pain Research and Management 2001, 203-213. IASP Press, Seattle, WA. P.T. Hansson, H.L. Fields, R.G. Hill (Eds.).
20. Elliott T.E., Renier C.M., Palcher J.A. Chronic pain, depression, and quality of life: correlations and predictive value of the SF-36. Pain Med 2003, 4:331-339.
21. Romano J.M., Turner J.A. Chronic pain and depression: does the evidence support a relationship?. Psychol Bull 1985, 97:18-34.
22. Otis J.D., Keane T.M., Kerns R.D. An examination of the relationship between chronic pain and post-traumatic stress disorder. J Rehabil Res Dev 2003, 40:397-405.
23. Deardorff W. Breaking the cycle of chronic pain and insomnia [web site], Accessed February 21, 2007. http://www.spine-health.com/topics/conserv/insom-nia/insomnia1.html.
24. Cohen M.J.M., Menefee L.A., Doghramji K., et al. Sleep in chronic pain: problems and treatments. Int Rev Psychiatry 2000, 12:115-126.
25. Barkin R.L. Zolpidem extended-release: a single insomnia treatment option for sleep induction and sleep maintenance symptoms. Am J Ther 2007, 14:299-305.
26. Jordan J.M., Bernard S.L., Callahan L.F., et al. Self-reported arthritis-related disruptions in sleep and daily life and the use of medical, complementary, and self-care strategies for arthritis: the National Survey of Self-care and Aging. Arch Fam Med 2000, 9:143-149.
27. Nighttime pain: a major problem for one out of three adults. Gallup survey says pain interrupts sleep. J Pract Nurs 1996, 46:27-29.
28. Wilcox S., Brenes G.A., Levine D., et al. Factors related to sleep disturbance in older adults experiencing knee pain or knee pain with radiographic evidence of knee osteoarthritis. J Am Geriatr Soc 2000, 48:1241-1251.
29. Paiva T., Farinha A., Martins A., et al. Chronic headaches and sleep disorders. Arch Intern Med 1997, 157:1701-1705.
30. Pilowsky I., Crettenden I., Townley M. Sleep disturbance in pain clinic patients. Pain 1985, 23:27-33.
31. Affleck G., Urrows S., Tennen H., et al. Sequential daily relations of sleep, pain intensity, and attention to pain among women with fibromyalgia. Pain 1996, 68:363-368.
32. Atkinson J.H., Slater M.A., Patterson T.L., et al. Prevalence, onset, and risk of psychiatric disorders in men with chronic low back pain: a controlled study. Pain 1991, 45:111-121.
33. Obermeyer W.H., Benca R.M. Effects of drugs on sleep. Neurol Clin 1996, 14:827-840.
34. Americans Living With Pain Survey. Executive Summary of Results. Survey conducted on behalf of the American Chronic Pain Association. Sponsored by Endo Pharmaceuticals. April 2004 [web site], Accessed February 21, 2007. http://theacpa.org/documents/FINAL%20PAIN%20SURVEY%20RESULTS%20REPORT.pdf.
35. Facts & Comparisons 4.0 [web site], Accessed July 25, 2007. http://www.factsandcomparisons.com/Products/index.%20aspx?cat=8%26id=1112.
36. The management of chronic pain in older persons: AGS Panel on Chronic Pain in Older Persons. J Am Geriatr Soc 1998, 46:635-651. American Geriatrics Society.
37. ® celecoxib tablets 2005, [package insert], G.D. Searle LLC, Division of Pfizer, New York, NY.
38. Katz W.A. Use of nonopioid analgesics and adjunctive agents in the management of pain in rheumatic diseases. Curr Opin Rheumatol 2002, 14:63-71.
39. Groarke J.F., Averett J.M., Hirschowitz B.I. Acetaminophen and hepatic necrosis. N Engl J Med 1977, 296:233.
40. McGoldrick M.D., Bailie G.R. Nonnarcotic analgesics: prevalence and estimated economic impact of toxicities. Ann Pharmacother 1997, 31:221-227.
41. Crofford L.J. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl 1997, 49:15-19.
42. K/DOQI Clinical Practice Guidelines for chronic kidney disease: evaluation, classification, and stratification National Kidney Foundation, [website], Accessed November 26, 2007. http://www.kidney.org/PROFESSIONALS/kdoqi/guidelines_CKD/P7_risk_G13.htm.
43. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998, 105:31S-38S.
44. McGettigan P., Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006, 296:1633-1644.
45. Page J., Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000, 160:777-784.
46. Buvanendran A., Barkin R. Lumiracoxib. DrugsToday (Barc) 2007, 43:137-147.
47. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000, 343:1520-1528.
48. Lanas A., Garcia-Rodriguez L.A., Arroyo M.T., et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut 2006, 55:1731-1738.
49. Schnitzer T.J., Burmester G.R., Mysler E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET): reduction in ulcer complications; randomised controlled trial. Lancet 2004, 364:665-674.
50. Venkat K., Brown M.D., Barkin R. Nonsteroidal anti-inflammatory drugs and gastroduodenal injury. Am J Ther 1998, 5:263-272.
51. Barkin R.L., Buvanendran A. Focus on the COX-1 and COX-2 agents: renal events of nonsteroidal and anti- inflammatory drugs-NSAIDs. Am J Ther 2004, 11:124-129.
52. Andersohn F., Suissa S., Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs and risk of acute myocardial infarction. Circulation 2006, 113:1950-1957.
53. Caldwell B., Aldington S., Weatherall M., et al. Risk ofcardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006, 99:132-140.
54. Fitzgerald G.A. Coxibs and cardiovascular disease. N Engl J Med. 2004, 351:1709-1711.
55. Nussmeier N.A., Whelton A.A., Brown M.T., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005, 352:1081-1091.
56. Barkin R.L., Barkin D. Pharmacologic management of acute and chronic pain: focus on drug interactions and patient-specific pharmacotherapeutic selection. South Med J 2001, 94:756-770.
57. Warner T.D., Mitchell J.A. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004, 18:790-804.
58. Perazella M.A., Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med 2001, 111:64-67.
59. Langford R.M. Pain management today: what have we learned?. Clin Rheumatol 2006, 25(suppl 7):2-8.
60. McHughes M., Lipman A.G. Managing osteoarthritis pain when your patient fails simple analgesics and NSAIDs and is not a candidate for surgery. Curr Rheumatol Rep 2006, 8:22-29.
61. ® fentanyl transdermal system 2005, [package insert], Janssen Pharmaceutical Products, LP, Titusville, NJ.
62. ® tramadol hydrochloride tablets 2004, [package insert], Ortho-McNeil Pharmaceutical, Raritan, NJ.
63. Gutstein H.B., Akil H. Opioid analgesics. Goodman & Gilman's The Pharmacological Basis of Therapeutics 2001, 569-620. McGraw-Hill, New York, NY. J.G. Hardman, L.E. Limbird, A. Goodman Gilman (Eds.).
64. Barkin R.L., Lubenow T.R., Bruehl S., et al. Management of chronic pain: part I. Dis Mon 1996, 42:389-454.
65. Cherny N.I. Opioid analgesics: comparative features and prescribing guidelines. Drugs 1996, 51:713-737.
66. Barkin R.L. Acetaminophen, aspirin, or ibuprofen in combination analgesic products. Am J Ther 2001, 8:433-442.
67. Barkin R.L. Methadone: a novel and potentially hazardous opioid analgesic. Pain Med Network 2006, 21:4-5. 11.
68. McCarberg B.H., Barkin R.L. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther 2001, 8:181-186.
69. Burgess F.W., Krantz M.J., Barkin R.L. Methadone: unintended mortality due to overdose and arrhythmia. Pain Med News 2007, 1-6. May/June.
70. Barkin R.L., Barkin S.J., Barkin D.S. Propoxyphene (dextro- propoxyphene): a critical review of a weak opioid analgesic that should remain in antiquity. Am J Ther 2006, 13:534-542.
71. Morley-Forster P.K., Clark A.J., Speechley M., et al. Attitudes toward opioid use for chronic pain: a Canadian physician survey. Pain Res Manage 2003, 8:189-194.
72. Barkin R.L., Iusco A.M., Barkin S.J. Opioids used in primary care for the management of pain: a pharmacologic, pharmacotherapeutic, and pharmacodynamic overview. Weiner's Pain Management: A Practical Guide for Clinicians 2006, 779-794. CRC Press, Boca Raton, FL. B.E. Cole, M.V. Boswell (Eds.).
73. ® ER (tramadol HCl) Extended-Release Tablets 2006, [package insert], PriCara, a unit of Ortho-McNeil, Raritan, NJ.
74. Raffa R.B., Friderichs E., Reimann W., et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 1992, 260:275-285.
75. Carlsson K.H., Jurna I. Effects of tramadol on motor and sensory responses of the spinal nociceptive system in the rat. Eur J Pharmacol 1987, 139:1-10.
76. Kayser V., Besson J.M., Guilbaud G. Evidence for a noradrenergic component in the antinociceptive effect of the analgesic agent tramadol in an animal model of clinical pain, the arthritic rat. Eur J Pharmacol 1992, 224:83-88.
77. Katz W.A. Pharmacology and clinical experience with tramadol in osteoarthritis. Drugs 1996, 52(suppl 3):39-47.
78. Rosow C.E., Moss J., Philbin D.M., et al. Histamine release during morphine and fentanyl anesthesia. Anesthesiology 1982, 56:93-96.
79. Babul N., Noveck R., Chipman H., et al. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage 2004, 28:59-71.
80. Murthy B.P., Skee D.M., Danyluk A.P., et al. Pharmacokinetic model and simulations of dose conversion from immediate- to extended-release tramadol. Curr Med Res Opin 2007, 23:275-284.
81. Cicero T.J., Inciardi J.A., Adams E.H., et al. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004. Pharmacoepidemiol Drug Saf 2005, 14:851-859.
82. Fishman S.M., Teichera D. Challenges and choices in drug therapy for chronic pain. Cleve Clin J Med 2003, 70:119-138.
83. Lynch M.E. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 2001, 26:30-36.
84. Maizels M., McCarberg B. Antidepressants and antiepileptic drugs for chronic non-cancer pain. Am Fam Phys 2005, 71:483-490.
85. Cavalieri T.A. Management of pain in older adults. J Am Osteopath Assoc 2005, 105(suppl 1):S12-S17.
86. Barkin R.L., Fawcett J. The management challenges of chronic pain: the role of antidepressants. Am J Ther 2000, 7:31-47.
87. Barkin R.L., Barkin S. The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical consider- ations of duloxetine pharmacotherapy. Am J Ther 2005, 12:431-438.
88. Bradley R.H., Barkin R.L., Jerome J., et al. Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. Am J Ther 2003, 10:318-323.
89. Barkin R.L., Schwer W.A., Barkin S.J. Recognition and management of depression in primary care: a focus on the elderly. A pharmacotherapeutic overview of the selection process among the traditional and new antidepressants. Am J Ther 2000, 7:205-226.
90. Moulin D.E., Clark A.J., Gilron I., et al. Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. Pain Res Manage 2007, 12:13-21.
91. Barkin R.L., Fawcett J., Barkin S.J. Chronic pain management with a focus on the role of newer antidepressants and centrally acting agents. Pain Management: A Practical Guide for Clinicians 2002, 1-20. CRC LLC Press, Boca Raton, FL. R.S. Weiner (Ed.).
92. Armstrong S.C., Cozza K.L., Sandson N.B. Six patterns of drug-drug interactions. Psychosomatics 2003, 44:255-258.
93. Manzi S.F., Shannon M. Drug interactions: a review. Clin Ped Emerg Med 2005, 6:93-102.
94. Mahlberg R., Kunz D., Sasse J., et al. Serotonin syndrome with tramadol and citalopram. Am J Psychiatry 2004, 161:1129.
95. Houlihan D.J. Serotonin syndrome resulting from co-administration of tramadol, venlafaxine, and mirtaza- pine. Ann Pharmacother. 2004, 38:411-413.
96. Kaye K. Trouble with tramadol. Aust Prescr 2004, 27:26-27.
97. ACPA Medications and Chronic Pain Supplement 2006 2006, American Chronic Pain Association, American Chronic Pain Association, Rocklin, California.
98. ® Lidocaine Patch 5% 2006, [package insert], Endo Pharmaceuticals, Chadds Ford, Pennsylvania.
99. Argoff C.E., Galer B.S., Jensen M.P., et al. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale. Curr Med Res Opin 2004, 20(suppl 2):S21-S28.
100. Gammaitoni A.R., Galer B.S., Onawola R., et al. Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the Neuropathic Pain Scale. Curr Med Res Opin 2004, 20(suppl 2):S13-S19.
101. Whelton A. Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non- NSAID analgesics. Am J Ther 2000, 7:63-74.
102. Wolfe M.M., Lichtenstein D.R., Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999, 340:1888-1899.
103. Scheiman J.M., Fendrick A.M. Summing the risk of NSAID therapy. Lancet 2007, 369:1580-1581.
104. Adriaensen H., Vissers K., Noorduin H., et al. Opioid tolerance and dependence: an inevitable consequence of chronic treatment?. Acta Anaesthesiol Belg 2003, 54:37-47.
105. Gilson A.M., Ryan K.M., Joranson D.E., et al. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J Pain Symptom Manage 2004, 28:176-188.
106. Thompson A.R., Ray J.B. The importance of opioid tolerance: a therapeutic paradox. J Am Coll Surg. 2003, 196:321-324.
107. Ferrel B.A., Ferrel B.R., Osterwell D. Pain in the nursing home. J Am Geriatr Soc. 1990, 38:409-414.
108. Herman A.D., Johnson T.M., Richie C.S., Parmelee P.A. Pain management interventions in the nursing home. A structured review of the literature. J Am Geriatr Soc 2009, 57:1258-1267. Published Online, June 3, 2009.
109. Stefanacci R. The pains of pain management today. Clinical Geriatrics September, 2009.
110. Gagliese L. Pain and aging: the emergence of a subfield of pain research. J Pain 2009, 10:343-353.
111. Gislason G.H., Rasmussen J.N., Abildstrom S.Z., Schramm T.K., et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009, 169:141-149. 26.
112. Katz W.A. Opioids for nonmalignant pain. Rheum Dis Clin N Am. 2008, 24:387-413.
113. Collins T.R. Opioids for Noncancer Pain a Subject of Hot Debate: An Expert Interview with Pain Specialist Ajay Wasan, MD, MSc Accessed February 24, 2010. http://http://www.medscape.com/viewarticle/717147_print.